From DCAT Value Chain Insights (VCI)
XBiotech, a biopharmaceutical company developing therapeutic antibodies, has named Kelly R. Thornburg as senior vice president of operations. Mr. Thornburg brings more than 30 years of pharmaceutical operations experience to XBiotech, the prior 16 years spent at Amgen, Inc.
Mr. Thornburg will oversee manufacturing operations for the production of the company’s proprietary humanized therapeutic antibodies. Among his duties, Mr. Thornburg will oversee the transition from Phase III clinical manufacturing to launch of commercial production. This will include oversight of the completion and validation of XBiotech’s commercial manufacturing facility now under construction.
Prior to joining XBiotech, Thornburg spent 16 years at Amgen where he held a variety of senior level positions. Thornburg served as an executive director, quality site head at Amgen’s Colorado facility, where he managed all aspects of Amgen’s quality functions with responsibility for two protein drug substance manufacturing plants and GMP warehouse facilities. Before that, Thornburg served as executive director, quality control, where he managed the quality control laboratory function for the Amgen manufacturing site in Juncos, Puerto Rico.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription